Current State of the First COVID-19 Vaccines

Birgit M Prüβ, Birgit M Prüβ

Abstract

SARS CoV-2 and its associated disease COVID-19 has devastated the world during 2020. Masks and social distancing could be efficient if done by large proportions of the population, but pandemic fatigue has decreased their efficacy. Economic shut downs come with large price tags and cannot be a long term solution either. The announcements by three vaccine manufacturers in November that their vaccines are 90% or more effective has given hope to at least those in the population who plan to get vaccinated as soon as a scientifically and medically sound vaccine becomes available. This review summarizes the underlying design strategies and current status of development of the nine vaccines that were in phase III trial on 8 November 2020. Contracts between vaccine manufacturing companies and governments aim at distributing the vaccine to a large part of the world population. Questions remain how the temperature sensitive mRNA vaccines will be transported and/or stored and how vaccination will be prioritized within each country. Additionally, current contracts do not cover all countries, with a serious gap in Africa and South America. The second part of this review will detail current distribution plans and remaining challenges with vaccine accessibility and acceptance.

Keywords: COVID-19; SARS CoV-2; phase III trial; vaccine development.

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Time line of vaccine production and approval. BP, BioNTech/Pfizer; M, Moderna; AZ, Oxford/Astra Zeneca; J&J, Janssen/Johnson and Johnson; NV, Novavax; SPV, Sputnik V; CoV, CoronaVac; Ad5, Ad5-nCOV; BCG, Mycobacterium bovis. Blue arrows, phase I/II trials; green arrows, phase III trials; yellow arrows, roll out; purple star, (anticipated) approval date. Trial start dates were taken from http://www.clinicaltrials.gov. Approximate end dates of phase I/II trials are the publication dates. End points for unpublished trials a4re guesses by the author. For the last three vaccines, a guess for an approval date was not possible. Note that all start and end dates of trials, as well as approval dates are approximations.

References

    1. Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: 10.1038/s41586-020-2012-7.
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Letko M., Marzi A., Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 2020;5:562–569. doi: 10.1038/s41564-020-0688-y.
    1. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032.
    1. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. doi: 10.1001/jama.2020.1585.
    1. Hu B., Huang S., Yin L. The cytokine storm and COVID-19. J. Med. Virol. 2020 doi: 10.1002/jmv.26232.
    1. Tsivgoulis G., Palaiodimou L., Katsanos A.H., Caso V., Köhrmann M., Molina C., Cordonnier C., Fischer U., Kelly P., Sharma V.K., et al. Neurological manifestations and implications of COVID-19 pandemic. Therapc. Adv. Neurol. Dis. 2020;13:1–14. doi: 10.1177/1756286420932036.
    1. Konturek P.C., Harsch I.A., Neurath M.F., Zopf Y. COVID-19-more than respiratory disease: A gastroenterologist’s perspective. J. Physiol. Pharmacol. 2020;71 doi: 10.26402/jpp.2020.2.02.
    1. Fraser E. Long term respiratory complications of covid-19. BMJ. 2020;370:m3001. doi: 10.1136/bmj.m3001.
    1. Troyer E.A., Kohn J.N., Hong S. Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms. Brain Behav. Immun. 2020;87:34–39. doi: 10.1016/j.bbi.2020.04.027.
    1. Tobías A. Evaluation of the lockdowns for the SARS-CoV-2 epidemic in Italy and Spain after one month follow up. Sci. Total Environ. 2020;725:138539. doi: 10.1016/j.scitotenv.2020.138539.
    1. Hsiang S., Allen D., Annan-Phan S., Bell K., Bolliger I., Chong T., Druckenmiller H., Huang L.Y., Hultgren A., Krasovich E., et al. The effect of large-scale anti-contagion policies on the COVID-19 pandemic. Nature. 2020 doi: 10.1038/s41586-020-2404-8.
    1. Krause K.L., Furneaux R., Benjes P., Brimble M., Davidson T., Denny W., Harris L., Hinkley S., Tyler P., Ussher J.E., et al. The post-lockdown period should be used to acquire effective therapies for future resurgence in SARS-Cov-2 infections. N. Z. Med. J. 2020;133:107–111. doi: 10.1056/NEJMp2031373.
    1. Ravi N., Cortade D.L., Ng E., Wang S.X. Diagnostics for SARS-CoV-2 detection: A comprehensive review of the FDA-EUA COVID-19 testing landscape. Biosens. Bioelectron. 2020;165:112454. doi: 10.1016/j.bios.2020.112454.
    1. Jahnel T., Kernebeck S., Böbel S., Buchner B., Grill E., Hinck S., Ranisch R., Rothenbacher D., Schüz B., Starke D., et al. Contact-tracing apps in contact tracing of COVID-19. Gesundheitswesen. 2020;82:664–669. doi: 10.1055/a-1195-2474.
    1. Steinbrook R. Contact Tracing, Testing, and Control of COVID-19-Learning From Taiwan. JAMA Intern. Med. 2020;180:1163–1164. doi: 10.1001/jamainternmed.2020.2072.
    1. Salathé M., Althaus C.L., Neher R., Stringhini S., Hodcroft E., Fellay J., Zwahlen M., Senti G., Battegay M., Wilder-Smith A., et al. COVID-19 epidemic in Switzerland: On the importance of testing, contact tracing and isolation. Swiss Med. Wkly. 2020;150:w20225. doi: 10.4414/smw.2020.20225.
    1. Chu D.K., Akl E.A., Duda S., Solo K., Yaacoub S., Schünemann H.J. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: A systematic review and meta-analysis. Lancet. 2020;395:1973–1987. doi: 10.1016/S0140-6736(20)31142-9.
    1. Prüß B.M. Current status of drug development against SARS CoV-2 infections. Med. Res. Arch. 2020;8 doi: 10.18103/mra.v8i8.2203.
    1. Chung Y.H., Beiss V., Fiering S.N., Steinmetz N.F. COVID-19 vaccine frontrunners and their nanotechnology design. ACS Nano. 2020;14:12522–12537. doi: 10.1021/acsnano.0c07197.
    1. Mulligan M.J., Lyke K.E., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Raabe V., Bailey R., Swanson K.A., et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586:589–593. doi: 10.1038/s41586-020-2639-4.
    1. Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2034577.
    1. Anderson E.J., Rouphael N.G., Widge A.T., Jackson L.A., Roberts P.C., Makhene M., Chappell J.D., Denison M.R., Stevens L.J., Pruijssers A.J., et al. Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2028436.
    1. Jackson L.A., Anderson E.J., Rouphael N.G., Roberts P.C., Makhene M., Coler R.N., McCullough M.P., Chappell J.D., Denison M.R., Stevens L.J., et al. An mRNA vaccine against SARS-CoV-2-preliminary report. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2022483.
    1. Folegatti P.M., Ewer K.J., Aley P.K., Angus B., Becker S., Belij-Rammerstorfer S., Bellamy D., Bibi S., Bittaye M., Clutterbuck E.A., et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020;396:467–478. doi: 10.1016/S0140-6736(20)31604-4.
    1. Ramasamy M.N., Minassian A.M., Ewer K.J., Flaxman A.L., Folegatti P.M., Owens D.R., Voysey M., Aley P.K., Angus B., Babbage G., et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): A single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020 doi: 10.1016/S0140-6736(20)32466-1.
    1. Voysey M., Clemens S.A.C., Madhi S.A., Weckx L.Y., Folegatti P.M., Aley P.K., Angus B., Baillie V.L., Barnabas S.L., Bhorat Q.E., et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020 doi: 10.1016/S0140-6736(20)32661-1.
    1. Keech C., Albert G., Cho I., Robertson A., Reed P., Neal S., Plested J.S., Zhu M., Cloney-Clark S., Zhou H., et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N. Engl. J. Med. 2020 doi: 10.1056/NEJMoa2026920.
    1. Logunov D.Y., Dolzhikova I.V., Zubkova O.V., Tukhvatullin A.I., Shcheblyakov D.V., Dzharullaeva A.S., Grousova D.M., Erokhova A.S., Kovyrshina A.V., Botikov A.G., et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: Two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020;396:887–897. doi: 10.1016/S0140-6736(20)31866-3.
    1. Zhu F.C., Li Y.H., Guan X.H., Hou L.H., Wang W.J., Li J.X., Wu S.P., Wang B.S., Wang Z., Wang L., et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: A dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395:1845–1854. doi: 10.1016/s0140-6736(20)31208-3.
    1. Zhu F.C., Guan X.H., Li Y.H., Huang J.Y., Jiang T., Hou L.H., Li J.X., Yang B.F., Wang L., Wang W.J., et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396:479–488. doi: 10.1016/S0140-6736(20)31605-6.
    1. Sahin U., Karikó K., Türeci Ö. mRNA-based therapeutics--developing a new class of drugs. Nat. Rev. Drug Discov. 2014;13:759–780. doi: 10.1038/nrd4278.
    1. Diken M., Kranz L.M., Kreiter S., Sahin U. mRNA: A versatile molecule for cancer vaccines. Curr. Issues Mol. Biol. 2017;22:113–128. doi: 10.21775/cimb.022.113.
    1. Feldman R.A., Fuhr R., Smolenov I., Ribeiro A., Panther L., Watson M., Senn J.J., Smith M., Almarsson Ӧ., Pujar H.S., et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37:3326–3334. doi: 10.1016/j.vaccine.2019.04.074.
    1. Pardi N., Weissman D. Nucleoside modified mRNA vaccines for infectious diseases. Methods Mol. Biol. 2017;1499:109–121. doi: 10.1007/978-1-4939-6481-9_6.
    1. Brouwer P.J.M., Caniels T.G., van der Straten K., Snitselaar J.L., Aldon Y., Bangaru S., Torres J.L., Okba N.M.A., Claireaux M., Kerster G., et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020;369:643. doi: 10.1126/science.abc5902.
    1. Pardi N., Tuyishime S., Muramatsu H., Kariko K., Mui B.L., Tam Y.K., Madden T.D., Hope M.J., Weissman D. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control. Release. 2015;217:345–351. doi: 10.1016/j.jconrel.2015.08.007.
    1. Sahin U., Muik A., Derhovanessian E., Vogler I., Kranz L.M., Vormehr M., Baum A., Pascal K., Quandt J., Maurus D., et al. COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature. 2020;586:594–599. doi: 10.1038/s41586-020-2814-7.
    1. Walsh E.E., Frenck R., Falsey A.R., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Mulligan M.J., Bailey R., et al. RNA-based COVID-19 vaccine BNT162b2 selected for a pivotal efficacy study. medRxiv. 2020 doi: 10.1101/2020.08.17.20176651.
    1. Tanne J.H. Covid-19: FDA panel votes to approve Pfizer BioNTech vaccine. BMJ. 2020;371:m4799. doi: 10.1136/bmj.m4799.
    1. Mahase E. Covid-19: UK approves Pfizer and BioNTech vaccine with rollout due to start next week. BMJ. 2020;371:m4714. doi: 10.1136/bmj.m4714.
    1. Tanne J.H. Covid-19: Pfizer-BioNTech vaccine is rolled out in US. BMJ. 2020;371:m4836. doi: 10.1136/bmj.m4836.
    1. Corbett K.S., Edwards D.K., Leist S.R., Abiona O.M., Boyoglu-Barnum S., Gillespie R.A., Himansu S., Schäfer A., Ziwawo C.T., DiPiazza A.T., et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020;586:567–571. doi: 10.1038/s41586-020-2622-0.
    1. Anderson B.R., Muramatsu H., Jha B.K., Silverman R.H., Weissman D., Karikó K. Nucleoside modifications in RNA limit activation of 2′-5′-oligoadenylate synthetase and increase resistance to cleavage by RNase L. Nucl. Acids Res. 2011;39:9329–9338. doi: 10.1093/nar/gkr586.
    1. Richner J.M., Himansu S., Dowd K.A., Butler S.L., Salazar V., Fox J.M., Julander J.G., Tang W.W., Shresta S., Pierson T.C., et al. Modified mRNA vaccines protect against Zika virus infection. Cell. 2017;168:1114–1125. doi: 10.1016/j.cell.2017.02.017.
    1. Hassett K.J., Benenato K.E., Jacquinet E., Lee A., Woods A., Yuzhakov O., Himansu S., Deterling J., Geilich B.M., Ketova T., et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol. Ther. Nucleic Acids. 2019;15:1–11. doi: 10.1016/j.omtn.2019.01.013.
    1. Corbett K.S., Flynn B., Foulds K.E., Francica J.R., Boyoglu-Barnum S., Werner A.P., Flach B., O’Connell S., Bock K.W., Minai M., et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med. 2020;383:1544–1555. doi: 10.1056/NEJMoa2024671.
    1. Ledford H. Moderna COVID vaccine becomes second to get US authorization. Nature. 2020 doi: 10.1038/d41586-020-03593-7.
    1. Ura T., Okuda K., Shimada M. Developments in viral vector-based vaccines. Vaccines. 2014;2:624–641. doi: 10.3390/vaccines2030624.
    1. Tan W.G., Jin H.T., West E.E., Penaloza-MacMaster P., Wieland A., Zilliox M.J., McElrath M.J., Barouch D.H., Ahmed R. Comparative analysis of simian immunodeficiency virus gag-specific effector and memory CD8+ T cells induced by different adenovirus vectors. J. Virol. 2013;87:1359–1372. doi: 10.1128/JVI.02055-12.
    1. Graham S.P., McLean R.K., Spencer A.J., Belij-Rammerstorfer S., Wright D., Ulaszewska M., Edwards J.C., Hayes J.W.P., Martini V., Thakur N., et al. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. NPJ Vaccines. 2020;5:69. doi: 10.1038/s41541-020-00221-3.
    1. van Doremalen N., Lambe T., Spencer A., Belij-Rammerstorfer S., Purushotham J.N., Port J.R., Avanzato V.A., Bushmaker T., Flaxman A., Ulaszewska M., et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020;586:578–582. doi: 10.1038/s41586-020-2608-y.
    1. Winslow R.L., Milligan I.D., Voysey M., Luhn K., Shukarev G., Douoguih M., Snape M.D. Immune responses to novel adenovirus type 26 and modified vaccinia virus Ankara–vectored Ebola vaccines at 1 Year. JAMA. 2017;317:1075–1077. doi: 10.1001/jama.2016.20644.
    1. Bos R., Rutten L., van der Lubbe J.E.M., Bakkers M.J.G., Hardenberg G., Wegmann F., Zuijdgeest D., de Wilde A.H., Koornneef A., Verwilligen A., et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines. 2020;5:91. doi: 10.1038/s41541-020-00243-x.
    1. Tostanoski L.H., Wegmann F., Martinot A.J., Loos C., McMahan K., Mercado N.B., Yu J., Chan C.N., Bondoc S., Starke C.E., et al. Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters. Nat. Med. 2020 doi: 10.1038/s41591-020-1070-6.
    1. Mercado N.B., Zahn R., Wegmann F., Loos C., Chandrashekar A., Yu J., Liu J., Peter L., McMahan K., Tostanoski L.H., et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020;586:583–588. doi: 10.1038/s41586-020-2607-z.
    1. Mahase E. Covid-19: Johnson and Johnson vaccine trial is paused because of unexplained illness in participant. BMJ. 2020;371:m3967. doi: 10.1136/bmj.m3967.
    1. Bangaru S., Ozorowski G., Turner H.L., Antanasijevic A., Huang D., Wang X., Torres J.L., Diedrich J.K., Tian J.H., Portnoff A.D., et al. Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate. Science. 2020;370:1089–1094. doi: 10.1126/science.abe1502.
    1. . Novavax Announces Positive Phase 1 Data for Its COVID-19 Vaccine Candidate. Novavax; Gaithersburg, MA, USA: 2020.
    1. Guebre-Xabier M., Patel N., Tian J.H., Zhou B., Maciejewski S., Lam K., Portnoff A.D., Massare M.J., Frieman M.B., Piedra P.A., et al. NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine. 2020 doi: 10.1016/j.vaccine.2020.10.064.
    1. Lu S. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 2009;21:346–351. doi: 10.1016/j.coi.2009.05.016.
    1. Burki T.K. The Russian vaccine for COVID-19. Lancet Respir. Med. 2020;8:e85–e86. doi: 10.1016/S2213-2600(20)30402-1.
    1. Callaway E. Russia’s fast-track coronavirus vaccine draws outrage over safety. Nature. 2020;584:334–335. doi: 10.1038/d41586-020-02386-2.
    1. Bucci E., Andreev K., Björkman A., Calogero R.A., Carafoli E., Carninci P., Castagnoli P., Cossarizza A., Mussini C., Guerin P., et al. Safety and efficacy of the Russian COVID-19 vaccine: More information needed. Lancet. 2020;396:e53. doi: 10.1016/S0140-6736(20)31960-7.
    1. Wu S., Zhong G., Zhang J., Shuai L., Zhang Z., Wen Z., Wang B., Zhao Z., Song X., Chen Y., et al. A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge. Nat. Commun. 2020;11:4081. doi: 10.1038/s41467-020-17972-1.
    1. Palacios R., Patiño E.G., de Oliveira Piorelli R., Conde M., Batista A.P., Zeng G., Xin Q., Kallas E.G., Flores J., Ockenhouse C.F., et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac-PROFISCOV: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21:853. doi: 10.1186/s13063-020-04775-4.
    1. Arts R.J.W., Moorlag S., Novakovic B., Li Y., Wang S.Y., Oosting M., Kumar V., Xavier R.J., Wijmenga C., Joosten L.A.B., et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe. 2018;23:89–100.e5. doi: 10.1016/j.chom.2017.12.010.
    1. Curtis N., Sparrow A., Ghebreyesus T.A., Netea M.G. Considering BCG vaccination to reduce the impact of COVID-19. Lancet. 2020;395:1545–1546. doi: 10.1016/S0140-6736(20)31025-4.
    1. Gopalaswamy R., Ganesan N., Velmurugan K., Aravindhan V., Subbian S. The strange case of BCG and COVID-19: The verdict is still up in the air. Vaccines. 2020;8:612. doi: 10.3390/vaccines8040612.
    1. Moorlag S., van Deuren R.C., van Werkhoven C.H., Jaeger M., Debisarun P., Taks E., Mourits V.P., Koeken V., de Bree L.C.J., Ten Doesschate T., et al. Safety and COVID-19 symptoms in individuals recently vaccinated with BCG: A retrospective cohort study. Cell Rep. Med. 2020;1:100073. doi: 10.1016/j.xcrm.2020.100073.
    1. Ozdemir C., Kucuksezer U.C., Tamay Z.U. Is BCG vaccination affecting the spread and severity of COVID-19? Allergy. 2020;75:1824–1827. doi: 10.1111/all.14344.
    1. Callaway E. What Pfizer’s landmark COVID vaccine results mean for the pandemic. Nature. 2020 doi: 10.1038/d41586-020-03166-8.
    1. Callaway E. COVID vaccine excitement builds as Moderna reports third positive result. Nature. 2020;587:337–338. doi: 10.1038/d41586-020-03248-7.
    1. Dooling K. COVID-19 Vaccine Prioritization: Work Group Considerations. Center for Disease Control and Prevention; Atlanta, GA, USA: 2020.
    1. . COVID-19 Vaccination Program Interim Playbook for Jurisdiction Operations. Center for Disease Control and Prevention; Atlanta, GA, USA: 2020.
    1. . JCVI: Updated Interim Advice on Priority Groups for COVID-19 Vaccination. Department of Health and Social Care; UK: 2020.
    1. Payne C. COVID-19 in Africa. Nat. Hum. Behav. 2020;4:436–437. doi: 10.1038/s41562-020-0870-5.
    1. Haider N., Yavlinsky A., Simons D., Osman A.Y., Ntoumi F., Zumla A., Kock R. Passengers’ destinations from China: Low risk of Novel Coronavirus (2019-nCoV) transmission into Africa and South America. Epidemiol. Infect. 2020;148:e41. doi: 10.1017/S0950268820000424.
    1. El-Sadr W.M., Justman J. Africa in the Path of Covid-19. N. Engl. J. Med. 2020;383:e11. doi: 10.1056/NEJMp2008193.
    1. Xu B., Kraemer M.U.G., Open COVID-19 Data Curation Group Open access epidemiological data from the COVID-19 outbreak. Lancet Infect. Dis. 2020;20:534. doi: 10.1016/S1473-3099(20)30119-5.
    1. Karafillakis E., Larson H.J. The benefit of the doubt or doubts over benefits? A systematic literature review of perceived risks of vaccines in European populations. Vaccine. 2017;35:4840–4850. doi: 10.1016/j.vaccine.2017.07.061.
    1. Cobos Muñoz D., Monzón Llamas L., Bosch-Capblanch X. Exposing concerns about vaccination in low- and middle-income countries: A systematic review. Int. J. Public Health. 2015;60:767–780. doi: 10.1007/s00038-015-0715-6.
    1. Ensering M., Cohen J. Fact-checking Judy Mikovits, the controversial virologist attacking Anthony Fauci in a viral conspiracy video. Science. 2020 doi: 10.1126/science.abc7103.
    1. Lazarus J.V., Ratzan S.C., Palayew A., Gostin L.O., Larson H.J., Rabin K., Kimball S., El-Mohandes A. A global survey of potential acceptance of a COVID-19 vaccine. Nat. Med. 2020:1–4. doi: 10.1038/s41591-020-1124-9.
    1. Malik A.A., McFadden S.M., Elharake J., Omer S.B. Determinants of COVID-19 vaccine acceptance in the US. E Clin. Med. 2020;26:100495. doi: 10.1016/j.eclinm.2020.100495.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren